I am a
Home I AM A Search Login

Papers of the Week

Papers: 19 Mar 2022 - 25 Mar 2022

Human Studies

2022 Mar 19

J Headache Pain



Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.


Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B, Gendolla A, Barbanti P, Aurilia C, Egeo G, Cevoli S, Favoni V, Vernieri F, Altamura C, Russo A, Silvestro M, Valle E D, Mancioli A, Ranieri A, Alfieri G, et al.
J Headache Pain. 2022 Mar 19; 23(1):38.
PMID: 35305579.


Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data mostly considered benefits in terms of relative efficacy (percent or absolute decrease in monthly migraine days [MMDs] or headache days compared with baseline). However, not enough attention has been paid to residual MMDs and/or migraine-related disability in treated patients. In the present study, we aimed at comparing the relative and absolute efficacy of erenumab.